Table 1. Clinicopathological features of the ALDH1A1-low group and ALDH1A1-high group (n = 60).
| ALDH1A1 expression | P | ||
|---|---|---|---|
| Low (n = 29) | High (n = 31) | ||
| Age (years) | 66.8 ± 10.6 | 70.9 ± 8.5 | 0.1021 |
| Sex (male/female) | 21/8 | 22/9 | 0.871 |
| BMI | 21.7 ± 3.1 | 22.9 ± 2.8 | 0.1408 |
| HBV infection (+/−) | 7/22 | 10/21 | 0.6812 |
| HCV infection (+/−) | 13/16 | 18/13 | 0.4432 |
| Liver background (Liver cirrhosis/chronic hepatitis/normal) | 7/16/2 | 10/20/1 | 0.7146 |
| Tumor diameter (mm) | 60.9 ± 45.5 | 29.9 ± 15.1 | 0.0019 |
| V (+/−) | 18/11 | 9/22 | 0.0208 |
| Pathology (wel/wel-mod/mod/mod-por/por) | 0/4/19/1/5 | 7/2/17/4/1 | 0.016 |
| T (1/2/3/4) | 4/7/18/0 | 5/19/7/0 | 0.0215 |
| Stage (I/II/III/IV) | 4/7/18/0 | 5/19/7/0 | 0.0215 |
| UICC stage (I/II/III/IV) | 11/18/0/0 | 22/9/0/0 | 0.0208 |
| HGF (ng/ml) | 0.39 ± 0.12 | 0.39 ± 0.11 | 0.9085 |
| CEA (ng/ml) | 2.9 ± 1.5 | 4.4 ± 3.6 | 0.367 |
| CA19-9 (U/ml) | 17.3 ± 19.6 | 34.4 ± 42.4 | 0.0728 |
| AFP (ng/ml) | 6586 ± 17174 | 998 ± 4101 | 0.0168 |
| PIVKA-II (mAU/ml) | 31311 ± 77257 | 133 ± 3993 | 0.0719 |
| Albumin (g/dl) | 3.7 ± 0.5 | 3.7 ± 0.4 | 0.7683 |
| Total bilirubin (mg/dl) | 0.77 ± 0.23 | 0.85 ± 0.30 | 0.2051 |
Statistically significant values are displayed in boldface.
Abbreviations: BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; V, lymphovascular invasion; wel, well differentiated; mod, moderately differentiated; por, poorly differentiated; UICC, Unio Internationalis contra Cancrum; HGF, hepatic growth factor; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; AFP, α-fetoprotein; PIVKA-II, protein induced by Vitamin K absence or antagonists-II.